dr. A.M.W. (Marco) Alings Full Professor
- Department of Cardiology
In 1993, Marco Alings received a PhD in cellular electrophysiology, and thereafter was trained in clinical cardiology at the Academic Medical Center (Amsterdam) and clinical electrophysiology at the University Medical Center Utrecht. He was a post-doctoral fellow in molecular cardiology at Vanderbilt University, Nashville, TN.
Since 2000, he is staff member of the department of cardiology at the Amphia Hospital, Breda, the Netherlands, where he acted as director of the residency program from 2008-2019. In 2005, he joined the Board of the Dutch Network for Cardiovascular Research (WCN; www.wcn.life), an association of 59 cardiovascular research centers, and served as Chair of the WCN from 2007 through 2013.
In 2014, Alings joined Julius Clinical (www.juliusclinical.com), a science oriented CRO that designs and manages global clinical drug trials, as Scientific Officer for cardiovascular studies.
As of 11-2019, he joined the Utrecht Trial Innovation Alliance (UTRIAL), which was designed to strengthen the UMCUtrecht's pursuit of ambitious goals in clinical trials across its six priority fields. Within Circulatory Health, Alings' focus will be on designing and executing clinical trials sponsored by pharmaceutical or medical device companies, as well as investigator and publicly funded trials.
Advisory board, steering committee or speakerbureau for Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb, Daiichi Sankyo, Milestone Pharmaceutical Inc, Pfizer, Roche Diagnostics, Sanofi